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ABSTRACT 
 
Betaine-homocysteine S-methyltransferase (BHMT) catalyzes the transfer 
of a methyl group from betaine to homocysteine to form dimethylglycine and 
methionine, respectively. BMHT is primarily expressed in the liver and kidney of 
mammals. BHMT catalyzes an ordered bi bi reaction where the first product 
released, dimethylglycine, can compete for the betaine binding site and inhibit 
homocysteine utilization. There is considerable interest in the regulation of 
homocysteine metabolism since even moderate elevations in plasma total 
homocysteine have been established as an independent risk factor for the 
development of vascular diseases and thrombosis. In people with 
homocystinuria, treatment using supplemental betaine showed a significant 
decrease in total plasma homocysteine but does not lower homocysteine levels 
within the normal range, and the moderate levels that remain are highly 
correlated with vascular disease. Therefore, the BHMT catalyzed reaction is a 
target for the treatment of homocystinuria. Finding alternative methyl donors for 
the BHMT reaction that following methyl transfer have less potent inhibitory 
properties than dimethylglycine are desired. Sulfonium analogs of betaine are 
considered for this research. The main objectives of this research were to 
determine the inhibitory properties of the demethylated product of betaine and its 
sulfonium analogs and also to determine the Michaelis constants in order to use 
them as alternative methyl donors for the BHMT reaction in homocystinuric 
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patients. The methyl donor substrates used are betaine, dimethylsulfonioacetate, 
dimethylsulfoniopropionate, and their respective demethylated products are 
dimethylglycine, methylthioacetate and methylpropionate. Dimethylglycine had 
the lowest IC50 values, ranging from 28 to 35 µM for all three enzymes. 
Methylthioacetate had IC50 values ranging from 65 to 106 µM, and values for 
methylthiopropionate ranged from 400 to 800 µM. There was no significant 
difference between the IC50 values obtained for the different enzymes when 
assayed in the presence of DMG or MTA, but for MTP the IC50 values were 
significantly different from one enzyme to another.  Kinetic studies for betaine 
was conducted for all three enzymes. The Km of betaine varied from 1.8±0.5 mM, 
0.7±0.06, and 0.5±0.06 mM for overexpressed human BHMT, pig and rat liver 
BHMT, respectively. We are unable to determine the Km for DMSA and DMSP. 
Further studies as the catalytic efficient (Kcat) for all three substrates are needed 
in other to determine which one could be a better alternative treatment for 
homocystinuria.  
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CHAPTER 1 
 
Literature Review 
Introduction 
  Vascular diseases, particularly heart disease and stroke, are the leading causes 
of death in the United States1. Atherosclerosis, a process commonly referred to as 
“hardening of the arteries”, is the most prevalent form of vascular disease. 
Atherosclerosis can affect the arteries of the heart (cardiovascular disease), the brain 
(cerebrovascular disease), and the legs (peripheral vascular disease). Due to the 
prevalence of vascular diseases, efforts to reduce their incidence have increased 
research in an effort to understand the underlying causes with the overall aim to 
decrease morbidity and mortality. The primary risk factors for vascular disease include 
high blood pressure, high blood cholesterol, smoking, and physical inactivity. It is 
estimated that about half of the adults in the US have at least one of these factors. More 
recently, elevated levels of plasma total homocysteine (tHcy), or hyperhomocysteinemia 
(HHcy), has been proposed to be an independent risk factor for cardiovascular 
diseases. In 1993, Allen and Stabler suggested that even mild increases of tHcy in the 
range of 16 to 25 µmol/L are highly correlated with all major forms of vascular diseases 
including coronary artery, cerebral and peripheral vascular2. A meta-analysis by 
Boushey et al. showed that tHcy is a strong, independent, and graded risk factor for 
atherosclerotic disease in coronary, peripheral, and cerebral vessels3.  
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Homocysteine and Diseases 
 
Homocysteine (Hcy) is derived from the essential amino acid methionine (Met). It 
is an intermediate of sulfur amino acid metabolism and is not found in proteins. The 
level of Hcy in blood and tissues is kept very low. In its reduced form Hcy it has a free 
thiol group that is susceptible to auto-oxidation at physiological pH to form disulfide 
bonds. In plasma, only about 1% of Hcy exists in the reduced form, and about 70% is in 
disulfide linkage with the cysteine (Cys) residues found in plasma proteins, 
predominantly albumin. The remainder of the Hcy (~30%) is found in disulfide linkage 
with other low molecular-weight sulfur containing compounds, primarily Cys4. Together 
these forms are called tHcy. In humans, levels of tHcy increase throughout life in both 
men and women (see table 1)5, 6. As mentioned previously, Hcy is normally kept very 
low in tissues, and normal levels of fasting tHcy are considered to be between 5 and 15 
µmol/L (see table 1)4.5. Elevated levels of tHcy are grouped into three levels; moderate, 
intermediate or severe, and any level above normal is called HHcy. 
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Table 1. Plasma total homocysteine (tHcy) levels for men and women, and 
classification 
Age range 5 Under 30 years 30-50 years Over 60 years 
tHcy Levels µM, Men and 
Women 5 
4.1- 8.1 4.5- 11.2  5.8 – 11.9 
tHcy- Classification 5 Moderate Intermediate Severe 
[tHcy] µmol/L5,6 16 – 30  31- 100 >100 
 
The kidney has an important role in the clearance and metabolism of Hcy. Under 
normal conditions, Hcy is filtered at the glomerulus and is reabsorbed in the tubules and 
metabolized7. Homocystinuria is a pathological condition concomitant with severe HHcy.  
It is when Hcy accumulates as such high levels that the disulfide form of Hcy, 
homocystine, accumulates and spills over into the urine. HHcy and homocystinuria 
result from disturbances in Met metabolism that are typically due to a genetic defect or a 
vitamin-derived coenzyme deficiency that affect the proteins needed for normal sulfur 
amino acid metabolism. The most common genetic defects that cause homocystinuria 
are mutations in the cystathionine beta synthase (CBS) gene, which encodes an 
enzyme in the transsulfuration pathway required for the degradation of Hcy. More rare 
genetic causes of homocystinuria are due to mutations in genes encoding 
methylenetetrahydrofolate reductase (MTHFR) or genes involved in cobalamin 
metabolism. Deficiencies of folate, vitamin B12 or vitamin B6 can also cause HHcy 
because of the role their derived coenzymes have in sulfur amino acid metabolism. 
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Details of the genes/enzyme and their required coenzymes are discussed in more detail 
below.  
Biochemical and pathological studies in homocystinuric children proposed that 
elevated tHcy may cause arteriosclerosis8 while other clinical studies in humans have 
suggested that elevated tHcy is an independent risk factor for atherosclerotic vascular 
diseases, and arterial and venous thromboembolism. Moderate to intermediate HHcy is 
present in 12-47% of patients with coronary, cerebral, or peripheral arterial occlusive 
disease. Patients with fasting tHcy ranging from 15 – 50 µM are at increased risk for 
vascular disorders9. Strong evidence for a causal relationship is accumulating. 
Researchers observed that individuals with defective CBS or genes involved in 
cobalamin metabolism had severe premature thrombosis disease, and elevated tHcy 
was the only common metabolic disturbance10. Therefore, finding alternative strategies 
to reduce tHcy levels in homocystinuric patients is key factor to treat the disease. A 
number of therapeutic trials have used high dietary betaine and/or B-vitamins to reduce 
tHcy. These trials show that these treatments can drastically reduce tHcy, but not 
enough to normalize tHcy and the levels that remain are still strongly correlated to 
vascular disease risk. The research presented in this thesis describes preliminary 
enzymology using other alternatives to reduce tHcy levels with the hope they can 
normalize tHcy in individuals with moderate to severe HHcy.  
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Overview of Sulfur Amino Acid Metabolism and Choline Metabolism  
Sulfur Amino Acid Metabolism  
Amino acids are the structural units that make up proteins. They form short chain 
polymers called peptides, or long chain polymers called polypeptides. Amino acids are 
essential in the human diet because proteins are critical for maintenance and growth of 
the human body. Proteins contain twenty amino acids and only two of these, Met and 
Cys, contain the element sulfur. Also, among the twenty, nine cannot be synthesized by 
the human body and are therefore essential to have in the diet. Not only does Met 
contain sulfur, but it is also one of the essential amino acids. Besides being needed for 
protein synthesis, Met contributes substantially to the maintenance and integrity of 
cellular systems by serving as a source of methyl groups by its conversion to S-
adenosylmethionine (SAM), and by its incorporation into glutathione, Met influences 
cellular redox state and cellular capacity to detoxify toxic compounds, free radicals and 
reactive oxygen species11.  
 
Methionine Cycle 
Besides being important for protein synthesis, Met has important role in 
methylation reactions following its conversion to S-adenosylmethionine (SAM), which is 
an intermediate of the so-called Met cycle (Fig 1. 1). The Met cycle begins with its 
conversion to SAM by the enzyme methionine adenosyltransferase, also known as MAT 
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(Fig 1. 1 reaction 1). SAM is then used by one of hundreds of methyltransferase 
enzymes (Fig 1. 1 Reaction 2) whereby the methyl group associated with the Met 
moiety is transferred to a methyl acceptor to form a methylated product and  
S-adenosylhomocysteine (SAH). SAM-dependent methylations occur on many different 
molecules including DNA, RNA, phospholipids and proteins. SAH is then hydrolyzed to 
form Hcy by a reaction catalyzed by SAH hydrolase (Fig 1. 1 reaction 3).  
Hcy is now at a metabolic branch point and has two possible fates; it can be 
methylated to reform Met (called remethylation) by either betaine-homocysteine S-
methyltransferase (BHMT; Fig 1. 1 reaction 10) or methionine synthase (MS; Fig 1. 1 
reaction 7), or it can participate in the transsulfuration pathway (Fig 1. reactions 4 and 5) 
whereby serine and Hcy are joined together by CBS (Fig 1. 1 reaction 4) to form 
cystathionine, which is then be hydrolyzed by cystathionase (Fig 1.1 reaction 5) to form 
Cys and α ketobutyrate. If intracellular Hcy production in extra hepatic tissues 
overwhelms its metabolism through the remethylation and transsulfuration pathways, 
excess Hcy is released into circulation and metabolized by the liver, and to a lesser 
extent, kidney.  It is important to note that, as depicted in Figure 1, folate and vitamin 
B12 are needed for the MS-dependent remethylation of Hcy, and that vitamin B6 is 
required for both enzymes of the transsulfuration pathway, which explains why 
deficiencies in these vitamins can result in some degree of HHcy.  
As already explained, both BHMT and MS can remethylate Hcy (Fig 1. 1 
reactions 10 and 7), however, they use difference sources of methyl groups. The direct 
source of methyl groups for the MS-catalyzed reaction comes from 
methylenetetrahydrofolate reductase (MTHFR; Fig 1. 1 reaction 6). This reaction 
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reduces a methylene group to a methyl group, which is then used by the MS reaction. 
Ultimately, the methylene group comes from serine and glycine via reactions that are 
not shown in Fig 1. 1.  For the BHMT-catalyzed reaction, the methyl donor is betaine, a 
compound that is an intermediate of the choline oxidation pathway.  The oxidation 
choline to betaine aldehyde, and then to betaine (Fig 1. 1 reactions 8 and 9) are 
discussed in more detail below. However, after betaine (also known as trimethylglycine) 
serves as a methyl donor for the BHMT reaction, the demethylated product is 
dimethylglycine (Fig 1. 1 reaction 10).   
 
Transsulfuration Pathway  
As stated previously, the transsulfuration pathway catalyzes the conversion of 
Hcy and serine to Cys and α-ketobutyrate. Cystathionine is an intermediate of the 
transsulfuration pathway, and Cys is the final sulfur-containing product. The pathway is 
called transsulfuration because the sulfur of Hcy is transferred to serine, and so the 
backbone of Cys comes from serine and only the thiol group comes from Hcy.  The 
transsulfuration pathway is irreversible, and the existence of this pathway is why Cys is 
not an essential amino acid. The transsulfuration pathway is believed to be primarily 
expressed in the liver, kidney, small intestine and pancreas, and it represents the 
primarily catabolic pathway for Met. A reduction or lack of CBS activity is the most 
common cause of homocystinuria because of an inability to degrade Hcy. There have 
been many mutations described in the CBS gene and there is considerable genetic 
heterogeneity in the disease due to CBS deficiency.  Homocystinuria due to severe 
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CBS deficiency causes severe growth and mental abnormalities, skeletal abnormalities, 
dislocation of the optic lens, and the most lethal consequence of having unstable 
hemodynamics resulting in fatal thrombosis. In severely affected individuals Cys 
becomes and essential amino acid, and the most common treatment is to supplement B 
vitamins (B6, B12 and folate) and betaine in an effort to enhance Hcy remethylation and 
stimulate any residual CBS activity. 
In normal individuals the transsulfuration pathway is important because it 
provides Cys, which is not only needed for protein synthesis, but is also a component of 
glutathione, a tripeptide that has a critical role in maintaining thiol redox status in the 
cell.  Glutathione is also involved in the detoxification of some drugs and xenobiotics in 
liver. In liver the concentration of glutathione is typically 5 to 10 millimolar. Cys is a 
precursor to taurine, a compound that is important in bile formation (taurocholic acid) 
and also functions as a renal osmolyte. Cys is also a precursor to sulfates, which are 
required for glycolipids, polysaccharides and sulpholipids, and hydrogen sulfide 
production, the latter of which is a gaseous molecule that has recently gained 
considerable attention since it has been discovered to be a signaling molecule. Hence, 
the transsulfuration pathway is very important to human health and function and 
insufficient flux through this pathway probably contributes to the pathologies observed in 
homocystinurics above and beyond simply having elevated levels of Hcy. 
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 Figure 1. 1 Methionine cycle and transsulfuration pathway: 1. Methionine Adenosyltransferase (MAT). 2. S-
Adenosylmethionine methyltransferase 3. S-Adenosylhomocysteine hydrolase 4. CBS 5. Cystathionase 6. MTHFR 7. 
Methionine Synthase 8. Choline dehydrogenase 9. Betaine aldehyde dehydrogenase 10. BHMT 
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Choline Metabolism and Oxidation 
Choline is a water soluble nutrient that is found in the diet and can also made 
from serine and Met in the liver. Although free choline is found in the diet, most dietary 
choline is associated with the phospholipid, phosphatidylcholine, also known as lecithin.  
Foods rich in lecithin include egg yolk and meats. For many years choline was not 
considered to be an essential nutrient as long as the diet contained adequate Met, 
however, in the late 1990s the Institute of Medicine’s declared choline to be an essential 
nutrient12. Choline deficiency results in fatty liver, which if not treated can develop into 
cirrhosis and hepatocellular carcinoma. The fatty liver is the result of a lack of 
phosphatidylcholine, which is required for lipoprotein (VLDL) synthesis and export of 
triglycerides out of the liver. The Institute of Medicine set the adequate intake of choline 
at 550 mg/day for adult men, and 425 mg/day for adult (non-pregnant, non-lactating) 
females12. 
An overview of choline metabolism is depicted in Figure 1.2 Its biosynthesis 
requires only one enzyme, phosphatidylethanolamine-N-methyltransferase (PEMT; Fig 
1.2, reaction 1), which converts phosphatidylethanolamine to phosphatidylcholine using 
three methyl groups derived from SAM. These methyl groups ultimately come from Met, 
as described in the section of sulfur amino acid metabolism on the Met Cycle (Fig 1.1). 
The ethanolamine moiety is derived from serine, which is why the synthesis of choline 
was previously stated to be possible from serine and Met. PEMT is a liver specific 
enzyme and accounts for about 30% of the phosphatidylcholine made in hepatocytes13.   
During normal phospholipid metabolism, the choline head group of 
phosphatidylcholine (and other choline-containing phospholipids not depicted) can be 
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removed to generate free choline. Choline is now at a branch point. It can either be re-
incorporated into the phospholipid pool (Fig 1.2, reactions 2 to 4), used to generate 
acetylcholine in nervous tissues (Fig 1.2 reaction 5), or oxidized to carbon dioxide an 
ammonium ion (a pathway depicted by step 7). These pathways are briefly discussed in 
the following paragraphs. 
The reincorporation of choline into phospholipids begins with its conversion to 
phosphocholine, which is catalyzed by choline kinase (Fig 1.2, reaction 2). 
Phosphocholine is further metabolized to phosphatidylcholine by the reactions catalyzed 
by CPT: phosphocholine cytidylytransferase (CT, and CPD-choline: 1, 2-diacylglycerol 
choline phosphotransferase (or choline phosphotransferase, CPT) (Fig 1. 2 reactions 3 
and 4). The regeneration of phosphatidylcholine that begins with the phosphorylation of 
choline is also known as the Kennedy pathway (Fig 1.2, reactions 2, 3 and 4). 
Another fate of free choline is mediated by its conversion to acetylcholine in 
nerve endings (axon terminals) by a reaction catalyzed by choline acetyltransferase (Fig 
1.2, reaction 5). There are many kinds of cholinergic nerve fibers, but perhaps the most 
familiar are those at the neuromuscular junction that stimulate muscle contraction by 
stimulating the acetylcholine receptor, which leads to skeletal muscle cell depolarization 
and contraction. Following release into the synapse, acetylcholine is acted upon by 
acetylcholine esterase (Fig 1.2, reaction 6), which lowers acetylcholine concentration 
and stops excitation at the acetylcholine receptor. Then, choline is pumped back into 
the nerve ending and reused for the synthesis of acetylcholine, stored in vesicles, and 
re-released into the neuromuscular synapse to initiate another cycle of muscle cell 
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depolarization and subsequent contraction. Quantitatively, acetylcholine stores 
represent a small fraction of total body choline. 
 
 
 
Figure 1. 2 Major biochemical pathways of choline metabolism. 1, biosynthesis of choline by the 
methylation of phosphatidyl-ethanolamine catalyzing by phosphatidyl-ethanolamine methyltransferase 
(PEMT). 2, acetylcholine synthesis (choline acetyltransferase). 3, hydrolysis (acetylcholinesterase). 4, 
choline oxidation. 6, choline kinase. 6, 7 reincorporation of choline into phosphatidylcholine, also known 
as Kennedy pathway (choline phosphorylation), phosphocholine cytidylytransferase and 
cholinephosphotranferase. 
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The final fate of free choline is that of oxidation. Choline oxidation is a major 
source of one carbon units and its oxidation occurs by a multistep process that is 
depicted in Figure 1.3. This process requires enzymes found both in the cytosol and the 
mitochondria, and these enzymes are very abundant in the liver and kidney. Free 
choline is transported into the mitochondria from the cytosol where it is oxidized to 
betaine aldehyde, and then betaine (Fig 1. 3). The enzymes catalyzing these reactions 
are choline dehydrogenase and betaine aldehyde dehydrogenase, respectively (Fig 1.3 
reactions 1 and 2). Betaine is then exported from the mitochondria to the cytosol where 
it becomes a substrate for the BHMT catalyzed reaction (Fig 1.3 reaction 3). The BHMT 
reaction transfers a methyl group from betaine to Hcy to form DMG and Met. DMG is 
transported from the cytosol into the mitochondria where it is metabolized to sarcosine 
then glycine by DMG dehydrogenase and sarcosine dehydrogenase, respectively (Fig 
1.3 reaction 4 and 5). Both reactions are folate- and flavin-dependent. The final reaction 
of choline oxidation is catalyzed by a protein complex called the glycine cleavage 
system (Fig 1.3 reaction 6). This enzyme system oxidizes glycine to produce MTHF, 
carbon dioxide and ammonium ion. The methylene groups associated with folate are 
then oxidized to formate in the mitochondria (not shown). Formate then leaves the 
mitochondria into the cytosol, becomes activated back into the folate pool, and can then 
use for the biosynthesis of purines, serine and Met (via the MTHF and MS; Fig 1.1 
reactions 6 and 7).  In total, choline oxidation contributes four carbons to the one-carbon 
pool via the formation of Met by BHMT, and the three MTHF molecules generated from 
DMG dehydrogenase, sarcosine dehydrogenase, and the glycine cleavage system 
(Fig1. 3). 
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The oxidation of choline to betaine is important because betaine is both a renal 
osmolyte and an important source of one carbon units to support Hcy remethylation and 
other one carbon needs by its production of MTHF14. Chiuve et al. demonstrated that 
the intake of betaine and choline was associated with lower tHcy in a cross-sectional 
analysis that included 1477 women15. In BHMT knockout mice, concentration of choline 
decreased and tHcy concentration increased (8-fold). Similarly, rats fed S-(-
carboxybutyl)-DL-homocysteine (CBHcy), a potent and specific inhibitor of BHMT, had 
decreased plasma choline and an increase in tHcy. These studies showed that BHMT is 
critical for tissue choline and Hcy homeostasis in rodents. At present, there is no report 
indicating there are humans that are deficient or lack BHMT activity, but the results from 
these studies strongly suggest that a mutation in the BHMT gene that results in reduced 
BHMT activity will have consequences for sulfur amino acid and choline metabolites.  
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Figure 1. 3 Enzymes in choline oxidation pathway:  1. Choline dehydrogenase 2. Betaine aldehyde 
dehydrogenase 3. Betaine homocysteine S-methyltransferase 4. Dimethylglycine dehydrogenase 5. 
Sarcosine dehydrogenase 6. Glycine cleavage. NAD and NADH: oxidized and reduced nicotinamide 
adenine dinucleotide. FAD and FADH: oxidized and reduced flavin adenine dinucleotide. THF: 
tetrahydrofolate. CH2THF: methylene tetrahydrofolate 
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Key Enzymes in Regulation of Sulfur Amino Acid Metabolism  
Methionine Adenosyltransferase (MAT) 
Methionine adenosyltransferase (MAT) is the enzyme that catalyzes the 
formation of SAM by joining together Met and the adenosyl moiety of ATP (Fig 1. 1 
reaction 1). In mammalian tissues, there are three distinct forms of MAT; MATI, MATII 
and MATIII, and these proteins are the products of two different genes, MAT1A and 
MAT2A16.  MAT1A is expressed only in the liver and encodes MATI (tetramer) and 
MATIII (dimer). MATIII is the dominant form and often times the formation of SAM in 
liver is ascribed to MATI/III activity. MAT2A is widely expressed in mammalian tissues, 
including liver, brain, and kidney encodes the MATII enzyme17, 18,19. In liver, MATII only 
represents about 5% of the total MAT activity. 
Although there are catalytic differences between MATI and MATIII, in general, 
the dominant characteristic of MAT activity in liver is that the activity has a high Km (Km = 
200-600 µM) and displays positive cooperatively (activated allosterically) with respect to 
SAM concentrations20. Sullivan and Hoffman showed that an increase in Met in the liver 
can increase SAM levels, which in turn further stimulates its own synthesis by 
allosterically activating MAT activity. The other form MAT II, primarily expressed in extra 
hepatic tissues and fetal liver, has a low Km for L-Met (6-8 µM), and has been shown to 
be strongly inhibited by SAM allosterically19.   
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Methyl Tetrahydrofolate Reductase (MTHFR) and Methionine Synthase (MS) 
MTHFR, a rate limiting enzyme for the MS-dependent remethylation of Hcy, is 
encoded by the MTHFR gene. It is a dimer that catalyzes the formation of 
methyltetrahydrofolate (MTHF) by reducing methylenetetrahydrofolate (Fig 1. 1 reaction 
6). This reaction is irreversible under both in vivo and in vitro conditions, and the 
enzyme activity is and potently inhibited (allosteric) by SAM21. MTHF is required for the 
MS reaction, one of the enzymes responsible for the de novo synthesis of Met. MS also 
requires vitamin B12 (cobalamin) as a coenzyme22. MS actually catalyzes two methyl 
transfers, first, the methyl group of MTHF is transferred to cobalamin to form 
methylcobalamin. Then, methylcobalamin is used to methylate Hcy to form Met. By 
inhibiting MTHFR, SAM impairs regeneration of Met by decreasing MTHF availability.  
 
Cystathionine Beta Synthase (CBS)  
CBS catalyzes the first reaction of the transsulfuration pathway. CBS is a 
tetrameric protein composed of identical subunits23 that is dependent on pyridoxal 
phosphate (PLP) and heme for activity24. This reaction represents one of the two major 
metabolic avenues to clear Hcy, and therefore its activity is critical to avoid an elevated 
level of Hcy, which increases risk for vascular diseases. SAM is a required allosteric 
activator of CBS25, stimulating flux through the transsulfuration pathway.  
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Betaine Homocysteine S-Methyltransferase (BHMT) 
Betaine homocysteine methyltransferase (BHMT) is a zinc metalloenzyme that 
catalyzes a methyl transfer from betaine to Hcy to form DMG and Met, respectively. 
This enzyme belongs to a family of enzymes that methylate thiols or selenols, a family 
that includes MS. BHMT is a tetramer made up of identical monomers. Moreover, 
BHMT is only expressed in liver and kidney.  BHMT catalyzes an ordered bi bi 
reaction26 whereby Hcy binds first, and then its binding causes a conformational change 
in the enzyme that creates the betaine binding site. Then, betaine binds and methyl 
transfer takes place followed by an ordered release of products, first DMG, and then 
Met. 
Betaine is the only methyl donor for the BHMT reaction that is made in the body, 
but we can also get betaine in the diet. Besides serving as a methyl donor for the BHMT 
reaction, betaine has an important role as a cellular osmolyte that protects cells from 
changes in tonicity10. Therefore, changes in BHMT expression could have the potential 
to affect betaine levels and cellular volume. It is known that BHMT is strongly inhibited 
by its end product DMG. This potent inhibition is directly due to its catalytic mechanism 
as a bi bi reaction; after Hcy binds to the enzyme the second ligand binding site can be 
occupied by betaine or DMG. If betaine binds, catalysis proceeds, if DMG binds, the 
enzyme is in an abortive ternary complex that is unable to produce Met. This complex 
represents a potent form of inhibition for the BHMT reaction26. Therefore, inside a living 
cell, the flux through this reaction is not only determined by the concentration of 
substrates, but it is also determined by the concentration of the de-methylated product 
of the methyl donor and its affinity for the betaine site.  
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  Diet has been shown to affect BHMT activity. BHMT is regulated at the 
transcriptional level by dietary betaine and Met27. When Met is deficient, dietary betaine 
or choline induces BHMT activity by increasing the level of its mRNA and subsequent 
protein levels. Betaine supplementation has been shown to lower tHcy in both 
hyperhomocysteinemic rats and humans10, but this supplementation does not usually 
lower Hcy levels to within the normal range. Allen et al. showed that betaine treatment 
lowers tHcy to 30-80 µM and eliminates the occurrence of thromboembolism in patients 
with cobalamin and folate deficiency in patients with severe HHcy2. Kinetic studies using 
purified porcine BHMT indicates that DMG inhibits the enzyme in a competitive way 
respect to betaine, but in an uncompetitive way with respect to Hcy. Up to 37-fold 
increase in plasma DMG (250 µM) were observed in individuals receiving betaine for 
homocystinuria compared with a control population28. These data support the 
hypothesis that betaine treatment for homocystinuria results in a large increase in DMG, 
which in turn inhibits BHMT and probably limits the effectiveness of betaine as Hcy-
lowering treatment in homocystinurics. Therefore, we propose that a strategy to reduce 
tHcy further in individuals with homocystinuria is to find alternative methyl donor that is 
good substrate for BHMT, but whose demethylated product either doesn’t accumulate 
or less potently inhibits the BHMT reaction. In theory, these substrates could enhance 
the conversion of Hcy to Met and lower Hcy to a greater extent that can be achieved by 
betaine treatment. It is known that sulfonium analogs of betaine, such as 
dimethylsulfonioacetate (DMSA) and dimethylsulfoniopropionate (DMSP) can function 
as methyl donors for the BHMT reaction. However, how well these compounds serve as 
methyl donors have not been kinetically characterized. DMSA is a synthetic compound 
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while DMSP is a naturally occurring compound found in plants. The work presented in 
this thesis characterizes the kinetic properties of substrates and inhibitors of human, 
pig, and rat liver BHMT as well as finding alternative methyl donor for the BHMT 
reaction that may improve the treatment for homocystinuria.  
 
Integration of Sulfur Amino Acid Metabolism in Liver 
Control of sulfur amino acid metabolism in liver is acutely regulated by SAM 
concentrations. When the diet contains high levels of Met, the level of SAM increases 
due to the fact that the flux through MAT increases as a result of its high Km for Met. 
Hepatic MAT activity is further enhanced by the resulting increase in SAM, which 
activates (positive allosteric) the enzyme. High SAM inhibits the remethylation of Hcy by 
MS because SAM is an allosteric inhibitor of MTHFR, which reduces MTHF production. 
Moreover, the high level of liver SAM caused by high dietary Met activates Hcy 
degradation by stimulating the activity of CBS. In short, a high dietary level of Met 
increases liver SAM, which inhibits the reformation of Met from Hcy, and stimulates the 
degradation of Hcy via transsulfuration. Conversely, if Met levels are less than 
adequate, SAM levels are decreased which lifts the inhibition of MTHFR and reduces 
CBS activation, pushing Hcy toward remethylation.    
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CHAPTER 2 
 
DIMETHYLGLYCINE, METHYLTHIOACETATE AND METHYLTHIOPROPIONATE AS 
INHIBITORS OF BETAINE HOMOCYSTEINE METHYL TRANSFERASE (BHMT) 
 
 Introduction   
 Homocysteine (Hcy) is produced from methionine (Met) by a multi-step process 
beginning with the formation of S-adenosylmethionine (SAM). SAM is the substrate for 
many methyltransferases, all of which produce S-adenosylhomocysteine (SAH), which 
is then hydrolyzed to form adenosine and Hcy. There are several genetic diseases that 
interfere with the use of Hcy. The most common is a cystathionine--synthase (CBS) 
deficiency, a condition that slows or abolishes the condensation of Hcy and serine to 
form cystathionine. Less common genetic diseases result in a reduction in the 
conversion of Hcy to Met by the folate- and cobalamin-dependent reaction catalyzed by 
methionine synthase (MS) 29. For each of these diseases, Hcy accumulates abnormally 
high in blood and spills into the urine, a condition known as homocystinuria. 
Homocystinuria, a condition caused by severe hyperhomocysteinemia (HHcy), has 
been associated with thrombosis and atherosclerosis. The treatment for all forms of 
homocystinuria include supplemental betaine. The treatment focuses on reducing 
plasma total Hcy (tHcy) by enhancing its methylation by BHMT to form Met. This 
treatment significantly reduces tHcy but rarely normalizes it, and although the clinical 
prognosis is greatly improved, for example the most severe complication (thrombosis) is 
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significantly reduced, the levels of tHcy that remain are still highly correlated to the 
development of vascular disease. 
BHMT makes up 0.5-2% of the soluble protein in liver. It catalyzes a methyl 
transfer from betaine to Hcy to form dimethylglycine (DMG) and Met, respectively. The 
reaction mechanism is ordered bi bi, whereby Hcy is the first substrate to bind and Met 
is the last product off (Fig 2. 1). This reaction mechanism creates the possibility for a 
potent form of feedback inhibition. In the case of BHMT, once Hcy binds and the second 
ligand binding site is open for occupancy, either betaine or DMG can bind. If betaine 
binds, the methyltransferase reaction proceeds. However, if DMG binds to the BHMT-
Hcy binary complex, then an abortive ternary complex (BHMT-Hcy-DMG) forms that is 
inactive. It can be assumed that living cells have steady-state levels of Hcy, betaine and 
DMG, and therefore if conditions arise that cause an increase in DMG, the flux through 
the BHMT reaction could be depressed. Since supplemental betaine is a treatment for 
homocystinuria, any concomitant increase in DMG could limit the Hcy-lowering effect of 
betaine because of the reduction of active enzyme since some of it is tied up in the 
BHMT-Hcy-DMG ternary complex.  
Does a high level of betaine supplementation cause an accumulation of DMG 
and therefore limit the Hcy-lowering potential of the BHMT reaction?  Previous studies 
have shown that betaine supplementation significantly reduces tHcy, but does not 
normalize it, and the level of tHcy that remain are still highly correlated to Hcy-induced 
pathologies. This has been shown in humans and animal models. For example, human 
homocystinurics being treated with betaine experienced reductions in tHcy but large 
increases in plasma DMG2. In mice with HHcy due to a lack of CBS activity, high 
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betaine supplementation also lowered tHcy but the levels of DMG increased greatly10. In 
summary, when animals or humans are treated for HHcy with supplemental betaine 
there is limited success; major reductions in tHcy are observed, but normalization is not 
achieved because of the concomitant rise in DMG, which inhibits the availability of 
active enzyme through the formation of the BHMT-Hcy-DMG ternary complex. 
Previous work has shown that sulfonium analogs of betaine can function as 
methyl donor substrates for the BHMT reaction. We have a specific interest in 
dimethylsulfonioacetate (DMSA) and dimethylsulfoniopropionate (DMSP) (Fig 2.2) as 
potential alternatives to betaine for the treatment of homocystinuria. DMSA is a 
synthetic compound. DMSP, a naturally occurring compound found in algae and some 
terrestrial plants, is thought to be the major precursor of dimethyl sulfide, a gas that has 
a dominant role in biogenic sulfur emission31. It is possible that these sulfonium analogs 
of betaine might be better supplements for treating homocystinuric patients if their 
demethylated products inhibit BHMT to a lesser extent than DMG.  
The hypothesis is that betaine treatment lowers tHcy because it initially increases 
flux of Hcy to Met using BHMT, however, over time DMG accumulates and prevents 
further tHcy-lowering because it inhibits the BHMT reaction. Alternative methyl donors 
to lower tHcy are needed, and their de-methylated products need to have lower affinity 
for the BHMT-Hcy binary complex enzyme. If identified, these products will be less likely 
to limit the flux through BHMT or compete with BHMT Hcy-binary complex site. Hence, 
a key goal of this research is to find alternative methyl donors that may improve 
treatment for homocystinuria. The main objective of this chapter is to characterize the 
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de-methylated products from DMSA and DMSP, methylthioacetate (MTA) and 
methylthiopropionate (MTP), respectively, as inhibitors for the BHMT reaction (Fig 2.2).  
 
 
I. MATERIALS AND METHODS 
Materials and Method 
Ampicillin, zinc chloride (ZnCl2), isopropyl β-D-thiogalactopyranoside (IPTG), D, 
L-homocysteine thiolactone, Dowex 1x4, dimethyl-glycine (DMG) and β-
mercaptoethanol were obtained from sigma-Aldrich (St. Louis, MO). Methylthioacetate 
(MTA) and methylthiopropionate (MTP), Ethylenediaminetetraacetic acid (EDTA),  
Protease inhibitors, Tris (2-  
 
Figure 2. 1 BHMT ordered bi bi reaction with the sulfonium analogs of betaine and their respective 
demethylated products.   
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Figure 2. 2 Chemical structure of betaine and the sulfonium analogs of betaine, and their 
respective demethylated products. 
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Materials and Methods  
Reagents 
Ampicillin, zinc chloride (ZnCl2), isopropyl β-D-thiogalactopyranoside (IPTG), D, 
L-Hcy thiolactone, Dowex 1x4, dimethylglycine (DMG) and β-mercaptoethanol were 
obtained from Sigma-Aldrich (St. Louis, MO). Methylthioacetate (MTA) and 
methylthiopropionate (MTP), ethylenediaminetetraacetic acid (EDTA), protease 
inhibitors, Tris (2-carboxyethyl) phosphine (TCEP), Tris HCl, Tris base, bovine serum 
albumin (BSA) were obtained from Thermo Fisher Scientific (Pittsburgh, PA).  
 
Expression and BHMT purification procedure 
 Vectors containing the wild type BHMT cDNA were transformed into E.coli. Cells 
were added to 50 mL 2XYT media containing 50 µL of ampicillin (100mg/mL), and was 
incubated overnight in refrigerated shaker set at 20 °C, 250 rpm. When cells reached an 
optimal OD600 of about 0.5 – 0.6, the culture was then centrifuged at 20°C for 30 
minutes. The pellet was resuspended in 1 mL of 2XYT broth, and then transferred into a 
1 L flask containing 2XYT media, 1 mL of ampicillin (100mg/mL), and 1 mL of 250 µM 
ZnCl2.  The resuspended cells were allowed to grow at 37°C, 180 rpm. When the OD600 
reached 0.7 – 1.0, IPTG was added (0.5mL of 1M IPTG) for the induction of BHMT 
expression. Induced cells were then incubated overnight at 20 °C, 250 rpm. Following 
the induction, the cells were collected by centrifugation at 5000g for 90 minutes at 4°C. 
The cells pellet was resuspended in 20 mL of cold ice buffer. Cells were then lysed 
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using a French press at 1500 p.s.i, and then sonicated on ice at 1 minute intervals (5 
times) at 30% output with a Branson Digital Sonifier 450 (Branson Ultrasonics 
Corporation, Danbury, CT). The cell lysate was clarified by centrifugation at 15000g for 
90 minutes at 4°C. Then the enzyme was purified in the cold room using a chitin affinity 
column. The clarified lysate was applied (0.5 mL/min) to a chitin affinity column (10 mL) 
that had been equilibrated with buffer containing 20 mM of Tris buffer pH 8.0, 500 mM 
NaCl, 1 mM EDTA pH 8.0, and 0.1% of triton. The column was then washed with 500 to 
800 mL of the same buffer followed by 300 to 500 mL of buffer containing 20 Mm of Tris 
buffer pH 8.0, 500 mM NaCl, and 1 mM EDTA pH 8.0. Then 30 mL of elution buffer 
containing 20 mM of Tris buffer pH 8.0, 50 mM NaCl, 1 mM EDTA pH 8.0, and 30 µL of 
βME was added to the column, which was subsequently was capped and allowed to 
stand overnight. The BHMT was eluted from the column sitting overnight, and then 
aliquot and store at -80°C.  
 
 Preparation of Crude Extract for Rat Liver and Pig Liver BHMT 
Rat liver was purchased from Innovative Research Inc. (Novi, MI) and stored at 
 -80 °C. Five grams of rat liver was partially thawed, minced with scissors, and 
suspended in 20 mL Tris-phosphate buffer (25 mM phosphate pH 7.0, 25 mM Tris pH 
8.0, 0.5 mM EDTA, 5 mM βME, 200 µL protease) at 0 ºC. Then the mixture was 
homogenized for 30 seconds using a Power Gen 500 homogenizer (Fisher Scientific, 
Pittsburgh, PA). Following homogenization, the crude extract was centrifuged at 15000 
g for 90 minutes. The supernatant was collected and then dialyzed three times using 
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two different buffers. The first two dialyses were done in 1 L of 25 mM phosphate pH 
7.0, 25 mM Tris pH 8.0, 0.5 mM EDTA, 5 mM βME. The third dialysis buffer was 2 L 
containing 25 mM phosphate pH 7.0, 25 mM Tris pH 8.0, 0.5 mM EDTA, 5 mM βME 
and 10 % glycerol. After dialysis the crude extract was aliquot and stored at -80 ºC. The 
same preparation was used for the pig liver.  
 
BHMT Assay 
 BHMT activity was measured as described by Finkelstein and Mudd32 with 
several modifications. DL-Hcy was prepared by a procedure described by Duerre and 
Miller33. DL-Hcy thiolactone hydrochloride (15.4 mg) was dissolved in 400 µL of 2N 
sodium hydroxide. The solution was allowed to sit 5 min at room temperature (23°C). 
The reaction was then neutralized by the addition of 600 µL of a saturated solution of 
mono-potassium phosphate and used immediately in the BHMT assay. The standard 
assay contained 5 mM DL-Hcy, 2 mM betaine (0.1 µCi), and 50 mM Tris – HCl (pH 7.5). 
The final reaction volume was 0.5 mL. Reaction tubes were capped with the rubber 
stoppers and kept in ice water until the assay was started by transferring the tubes into 
a 37 °C water bath. Following 1h incubation, samples were chilled in ice water, and 2.5 
mL of water was added. The samples were applied to a Dowex 1X4 chloride (-) form (50 
– 100 mesh), column (0.6 X 3.75 cm), and the unreacted betaine was washed from the 
column with water (3 X 5 mL). DMG and Met were eluted into scintillation mixture vials 
with 3 mL of 1.5 N HCl. Seventeen mL of scintillation mixture (Ecolume, ICN) were 
added to each vial and counted. Blank vials contained all of the reaction components 
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except enzyme, and their values were subtracted from the sample values. All samples 
were assayed in duplicate.  
 
Inhibition Studies and IC50 Determination 
The BHMT assay was performed as described above except they contained a 
lower concentration of betaine (250 M) with higher radioactivity (0.5 Ci). The 
concentrations of inhibitors (DMG, MTA, and MTP) were varied as described in the 
results. An amount of enzyme was used so that no more than 10% of substrate was 
consumed at the lowest level of inhibitor tested. Inhibitor concentrations tested were 
consistent with standard protocols34. Final inhibitor concentrations ranged from 1.5 µM 
to 15 mM, 10 µM to 3 mM, and 10 µM to 50 mM for DMG, MTA, and MTP respectively. 
All samples were assayed in duplicate, and the blank values were subtracted from all 
the sample values. The blank contained all of the reaction components except enzyme 
and inhibitors. Each IC50 determination with a given enzyme and inhibitor was done at 
least four times to assure repeatability. 
 
Statistical Analysis 
For the IC50 determination, all the results were plotted using Graph Pad Prism 6.04 by 
non -linear progression curve fit. Data are presented as means ± SEM and means were 
compared using two way ANOVA. Post hoc differences were compared by Fisher LSD 
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and p-values of less than 0.05 were considered statistically significant and noted by 
different superscripts, as presented in Table 2. 1.  
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Results 
 
Apparent half maximal inhibitory concentration (IC50) of DMG, MTA and MTP for 
BHMT enzymes – Human BMHT was overexpressed in E.coli, purified, and then 
dialyzed before being used in IC50 assays. Pig liver and rat liver were both homogenized 
and dialyzed, and these crude extracts were used to determine the IC50 values. All 
enzymes were assayed at least four times with the demethylated product; DMG, MTA, 
and MTP at different concentrations as stated previously in the Methods section. 
Preliminary assay parameters were established to optimize assay factors and 
reproducibility. A minimum of 10 concentrations of each inhibitor were used, and each 
concentration was assayed in replicate for an accurate IC50 determination. We used 
equally spaced concentration ranges (3 fold or half –log dilutions). We first determined 
the percent inhibition at a high and a low concentration of each inhibitor. After those 
results were obtained, we were able to determine an apparent IC50 using a more 
extensive range of concentrations. IC50 values were determined for each enzyme-
inhibitor pair at least four times, from which a mean IC50 was calculated. 
 
Demethylated Product DMG 
The results obtained showed that the IC50 values for purified human, and pig and rat 
liver BHMT enzymes in the presence of DMG are low and similar for all three enzymes, 
ranging between 28 to 35 µM (Fig 2.3; table 2). The concentration ranges used in these 
experiments were 1.5 µM to 15 mM for all three enzymes. The lowest concentration of 
DMG inhibited only 2% of the BHMT enzymatic activity, while the highest concentration 
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of DMG inhibited activity more than 98%. Statistically, there was no significant 
difference between enzymes, which was expected, as we know that mammalian BHMT 
enzymes share greater than 95% amino acid identity.  
 
Demethylated product MTA  
For MTA, the IC50 was about threefold greater for all three enzymes compared to 
DMG, ranging between 65 to 106 µM (Fig 2.3; table 2).The concentration ranges used 
in these experiments were from 3 µM to 10 mM. The lowest concentration of MTA 
inhibited only 2% of the BHMT enzymatic activity, while the highest concentration of 
DMG inhibited greater than 98% of the BHMT enzymatic activity. Statistically, there was 
no significant difference between enzymes using MTA, but there was significant 
difference between DMG and MTA. DMG so far has the lowest IC50 concentration 
values. 
 
Demethylated product MTP 
In contrast, the demethylated product MTP showed significantly greater IC50 values 
compared to the DMG and MTA (Fig 2.3; table 2) for all enzymes. The concentration 
ranges used in these experiments were from 10 µM to 50 mM. The lowest concentration 
of MTP inhibited only 2% of the BHMT enzymatic activity, while the highest 
concentration of MTP inhibited greater than 96% of the BHMT enzymatic activity. The 
IC50 values for MTP were more than tenfold higher than the IC50 values obtained for 
DMG, and the values were different from one enzyme to another (table 2). For the 
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recombinant human enzyme, IC50 values were around 700 to 800 µM, for the pig liver 
enzyme values were around 600 µM, and finally for the rat liver enzyme values were 
around 400 µM. This variation in IC50 values between enzymes was not expected, but 
the increase in IC50 compared to DMG and MTA was expected and can be justified. An 
explanation of this result may be due to slight variations in their molecular structure 
around their active sites.  
 
Table 2. Apparent half maximal inhibitory concentration (IC50) values for 
human, rat, and Pig BHMT enzymes with the different demethylated products 
(DMG, MTA, MTP) 
IC50 values, µM* 
 DMG MTA MTP 
Human 30 ± 2a 89 ± 8b 436 ± 14c 
Rat 33 ± 2a 97 ± 3b 586 ± 26d 
Pig 30 ± 2a 95 ± 18b 792 ± 26e 
Values are means ±SEM. Means were compared by two-way analysis of variance, and different superscript indicates 
significant difference (p<0.05) 
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Figure 2. 3 Apparent half maximal inhibitory concentration (IC50) curves for the human BHMT 
enzyme with DMG, MTA, and MTP 
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DISCUSSION 
 
Under normal conditions Hcy is either remethylated to produce Met or degraded 
through the transsulfuration pathway. However, there are genetic conditions that 
impede the remethylation or degradation of Hcy and result in its accumulation. It has 
been observed that increased tHcy concentrations in humans correlates with increased 
risk of coronary, cerebral and peripheral vascular disease3. Since BHMT can use 
betaine to metabolize Hcy to Met, a high betaine diet has been tried as treatment for 
homocystinuric people. There are studies that have shown that supplemental betaine 
can lower but not normalize tHcy in homocystinurics. We hypothesize it is the 
accumulation of DMG that limits the effectiveness of betaine treatment. Therefore, we 
want to investigate whether alternative methyl donors, which result in different 
demethylated products, might be more effective than betaine for the treatment of 
homocystinuria. We developed an assay to evaluate the inhibitory properties of the 
three different demethylated products; DMG, MTA, and MTP for the BHMT reaction. 
DMG has been already reported as a potent inhibitor for the BMHT reaction26, 28. Long 
term treatment with betaine promotes accumulation of DMG. This accumulation further 
inhibits the BHMT reaction by binding to the binary complex BHMT-Hcy. When DMG 
binds to the BHMT-Hcy complex instead of betaine, an abortive ternary complex forms 
(BHMT-Hcy-DMG), which impedes the BHMT reaction to methylate Hcy. In a study 
done by Garrow (1996) using an assay that used saturating levels of Hcy and sub-
saturating levels of betaine, 50 µM of DMG inhibited about 70% of the BHMT activity35. 
Reported here, only a small concentration (28 -35 µM) of DMG inhibited BHMT activity 
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by 50%. The proposed hypothesis that DMG accumulates to further prevent the 
lowering of Hcy by inhibiting the reaction could be possible according to these data. It is 
known that the absorption, distribution, and metabolism of betaine into DMG is very fast 
in healthy people36. When betaine is supplemented in the diet of homocystinurics, DMG 
quickly accumulates and probably inhibits BMHT and therefore limits the effectiveness 
of betaine treatment. Why DMB accumulates is not known, but it is probably due to the 
inability of DMG dehydrogenase and sarcosine dehydrogenase to metabolize it to 
glycine fast enough to prevent its accumulation.  
 IC50 values for human, pig and rat BHMT enzymes for MTA were between 60 
and 95 µM. MTA has a relatively low IC50 value and therefore could also inhibit the 
BHMT reaction if it accumulates, but perhaps in a less potent way than DMG. In a study 
done by Garrow (1996) using an assay that used saturating levels of Hcy and sub-
saturating levels of betaine, 50 µM of MTA inhibited about 59% of the BHMT activity35, 
which is less than that reported for DMG and consistent with the results reported here. 
Comparing the chemical structures of DMG and MTA, DMG has a quaternary 
ammonium group whereas MTA has a methyl sulfonium group with the same 
tetrahedral geometry. Therefore, it was expected that the IC50 values for these 
compounds could be similar. However, since the IC50 of MTA was about threefold 
higher than DMG, it would be expected to inhibit the BHMT reaction to a lower extent. It 
is known that DMG could be degraded to sarcosine and glycine by the enzymes DMG 
dehydrogenase and sarcosine dehydrogenase, respectively, but very little is known 
about MTA degradation in the body. If MTA could degrade as soon as it is consumed it 
might not accumulate and compete with betaine for the BHMT-Hcy binary complex. 
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Besides the conversion of DMSA to MTA, there is not much known about the fate of 
MTA in animal systems.  
 After injecting 1.5 mmoles of different solutions of betaine analogs into rats, 
including DMSA, Slow et al. (2004) found that within 24 h 7.7% ± 0.7 µM of DMSA were 
excreted in the urine37. They also found a sulfoxide of MTA, which implied that there 
was a further metabolism of MTA37. The amount of sulfoxide detected was 138.4 
±15.8µM between 0 and 8 h and 33 ± 3.2µM between 8 and 24 h following the 
treatment37. This total of excretion is less than 1% of the total of DMSA that was 
administrated to the rats. The small detection of DMSA byproducts and even DMSA in 
urine excretion makes it challenging and unclear regarding the degradation of this 
compound. More studies are needed characterized the degradation and toxicity of MTA 
and any derived metabolites. 
In contrast to MTA and DMG, the IC50 values of MTP were much higher than 
DMG and MTA for all three enzymes. Having an additional methylene group might 
interfere with the capacity of MTP to inhibit the reaction, and compete with betaine for 
the BHMT-Hcy binary complex. Due to that structural difference, it was anticipated that 
the IC50 values for MTP might be higher than the previous compounds but would not be 
different from one enzyme to another. Mammalian BHMT enzymes share about 95% 
amino acid identity and so the variation observed between enzymes were unexpected.  
MTP should have reacted the same way for all three enzymes because of this particular 
characteristic, and no significant difference should exist between them in terms of IC50 
values. In terms of overall number when IC50 values are compared for DMG, MTA and 
MTP, the values for MTP are high compared to the low values obtained for DMG and 
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MTA. Several studies had reported that DMSP is a substrate for the BHMT reaction. 
Collinsova et al (2006) showed that DMSP is an effective post-Met load tHcy-lowering 
agent, and it even decreased the levels of tHcy in mice to a greater extent than 
betaine38. The catalytic constants of DMSP for BHMT has never been reported, and so 
it is not known whether the improved tHcy-lowering effect of DMSP was in part due to it 
being a better substrate, or whether it is entirely due to MTP being a weaker BHMT 
inhibitor.   
In the same study cited previously with MTA, Slow et al. were not able to detect 
the presence of MTP or its sulfoxide in the urine of rats after injecting DMSP, but 
approximately two-thirds of the DMSP was excreted in the urine37. Previous studies 
showed DMSP has good property as a substrate for the BHMT enzymatic reaction and 
lowering tHcy in vivo38, but very little is known about whether its demethylated product 
MTP is metabolized further in vivo or if it is the end product. To some extent it does 
metabolize but how significant it is needs to be evaluated, and determined if there is no 
risk of toxicity. Chicks and rats fed with supplemental MTP demonstrated growth 
depression and splenic hemosiderosis, and they reported levels of toxicity similar to Met 
toxicity39, 40. There is some evidence that supports the existence of an alternative 
pathway for Met catabolism called transamination, where MTP serves as an 
intermediate. During this reaction Met is transaminated to 4-methylthio-2-oxobutyrate, 
followed by oxidative decarboxylation to 3-methylthiopropionate, and in vitro this 
reaction appears to account for 80% of the Met oxidation when there is high dietary Met 
. Blom et al showed that patients with hepatic methionine deficiency degraded at least 
20% of their dietary Met via the transamination pathway, while in normal subjects 
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transamination of Met did exist but was quantitatively not important in Met catabolism, 
not even after Met loading 41. In contrast, some authors proposed that transamination 
might be significant in tissues which, unlike liver, do not contain the Met cycle30 and are 
relevant only at extremely high levels of Met and its metabolites. A better understanding 
of this pathway and what tissues perform it would help in the understanding of MTP 
metabolism. As well as for MTA, more understanding is needed for MTP metabolism 
and the fate of its by-products in the body.  
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Summary 
DMG display greater affinity for the BHMT-Hcy binary complex follows by MTA, 
and then MTP. The IC50 values for DMG and MTA are lower than 100 µM. MTP was 
less effective, and a much higher concentration was needed to inhibit the reaction. If 
DMG accumulation is the main reason for the ineffectiveness of betaine 
supplementation in lowering tHcy in homocystinurics, these data suggest supplementing 
with DMSA, and the subsequent production of MTA could behave the same as the 
betaine-DMG pair. Considering the fact that MTP has less affinity for the BHMT-Hcy 
binary complex, we can predict that DMSP might be a better alternative. But, further 
studies are needed to characterize the toxicity of the sulfonium analogs of betaine and 
how they are degraded in the body. Also, we need to know how well DMSA and DMSP 
can be used by BHMT, i.e., their catalytic efficiency, before considering their use as 
alternatives for homocystinuric people. The following chapter of this research 
characterizes the kinetic properties of betaine and the sulfonium analogs of betaine 
(DMSA and DMSP) using purified human enzyme.  
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CHAPTER 3 
 
KINETIC CHARACTERIZATION OF BETAINE AND SULFONIUM ANALOGS OF 
BETAINE 
Introduction 
Trimethylglycine, also known as betaine, is found in microorganisms, animals, and 
plants. In most organisms it is biosynthesized by the oxidation of choline. Interest 
betaine metabolism has increased because elevated levels of plasma total 
homocysteine (tHcy) in blood is associated with certain vascular diseases. Therapies 
focused on reducing tHcy due to cystathionine β-synthase (CBS) deficiency include high 
levels of its cofactor pyridoxal phosphate. But approximately 40% of patients with CBS 
are unresponsive to pyridoxine therapy. For this reason, folic acid and betaine have 
been used to stimulate the remethylation of homocysteine (Hcy) to methionine (Met) by 
5-methyltetrahydrofolate methyltransferase and betaine-homocysteine 
methyltransferase (BHMT), respectively. Betaine stimulation of BHMT is only partially 
effective for several reasons such as: DMG accumulation, which further inhibits the 
BHMT reaction, or Met accumulation, leading to hypermethioninemia.  
 Searching for other effective alternative treatments that can lower tHcy to a 
normal range is key. In vitro studies have shown that sulfonium analogs of betaine can 
be used as methyl donor substrates for the BHMT reaction, but it is not known if they 
would be effective treatments for human homocystinuria. Previous studies showed that 
sulfonium analogs of betaine, such as dimethylsulfonioacetate (DMSA)35 and 
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dimethylsulfoniopropionate (DMSP), could be used by the BHMT reaction. Now, we 
want to evaluate the possibility that they could serve as treatment with homocystinuric 
patients if they can be shown to better than betaine as methyl donor substrates for the 
BHMT enzyme. Our objective is to determine the Michaelis constants (Km) for betaine 
and the different sulfonium methyl donors for the BHMT reaction. First, we want to 
determine the Km of betaine because there is a discrepancy around its Km in the 
literature. A broad range of values have been reported despite the fact that the 
mammalian BHMT enzymes share greater than 95% amino acid identity. It is possible 
that this discrepancy is due to experimental error, most likely to an inappropriate over 
consumption of betaine when assayed at low substrate concentrations (non-initial rate 
conditions). As depicted in figure 3, the lines represent experimentally determined initial 
rate velocity rates versus substrate concentration. Because enzyme-catalyzed reactions 
are saturables, their rates of reaction do not give a linear response to increasing of 
substrate. The most common error in the determination of Km values is an over 
consumption of substrate when tested at very low levels resulting in non-initial rate 
conditions. Our hypothesis is that some values that have been reported in the literature 
are low because of this unintentional error (Fig 3. 1; blue curve represents the over 
consumption of substrate, and the green curve a normal curve at initial rate).  
Also, it would be to know how well the enzyme will use the other substrates, 
DMSA and DMSP. The inhibitory properties of the demethylated products of these 
sulfonium compounds, MTA and MTP, respectively, are now known. So far, MTP had 
the highest IC50 value, indicating it is not a potent inhibitor. However having a higher 
IC50 values is not the best indicator that the substrate will react with the BHMT reaction 
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as well as betaine. We want to define the maximal catalytic activity (turn over, Kcat) of 
these methyl donors so we can determine their catalytic efficiencies (Kcat/Km). Due to 
time limitations and technical difficulties, this research only reported data for the initial 
velocity rate for betaine using purified human BHMT, rat and pig liver BHMT. 
 
 
Figure 3. 1 Enzyme initial rate kinetic mechanism 
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Materials and Methods 
Reagents 
 D, L-homocysteine thiolactone, Dowex 1x4, dimethyl-glycine (DMG) and β-
mercaptoethanol were obtained from Sigma-Aldrich (St. Louis, MO).  Bovine serum 
albumin (BSA) were obtained from Thermo Fisher Scientific (Pittsburgh, PA). Rat liver 
was obtained from Innovative Research Inc. (Novi, MI). Pig liver was a gift from Dr. L. 
Rund, Department of Animal Sciences, University of Illinois. 
 
 Initial Rate Kinetics of methyl donors 
The BHMT standard assay was performed as described in chapter 2 with some 
modifications. Kinetic assays for all three enzymes (purified human, pig and rat liver) 
were conducted using the varying levels of betaine. Each assay contained [14C-methyl]-
betaine (0.5 µCi) and total betaine was varied from 0.25 to 20 mM. All the experimental 
data were obtained at fixed Hcy concentration (saturate levels, 100mM) and varying 
concentrations of betaine. To determine the kinetic constants, the production of nmol of 
Met/h or the reaction velocity was calculated. All experiments were repeated at least 
three times and in duplicate for each betaine concentration. The Km’s were estimated by 
plotting initial rate data according to the method of Hanes (1932) using a simple linear 
regression (r2 > 0.97). To compare the results GraphPad Prism 6.04 was also used. 
The ratio of the initial substrate concentration [S] to the reaction velocity is plotted 
against [S].  
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Data Analysis 
The data obtained were analyzed using one way analysis of variance to compare 
experimental to control values. Date are expressed as the mean ± standard 
deviation. Comparisons between groups were performed using least significant 
difference (LSD) test. Differences were considered significant at p<0.05. Results 
with different letter indicates significant difference (Fig 3.2).   
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 Results 
The results of these experiments are showed in figures 3.2 and 3.3. There was 
no significant difference between the two methods but there was significant difference 
between the enzymes. Michaelis constants for each BHMT enzyme was 1.83±0.5 mM, 
0.71±0.06 mM, and 0.54±0.06 mM for human, pig and rat, respectively. The Km for the 
rat liver and pig liver BHMT enzyme showed no significant difference between each 
other but both were significantly different from the human enzyme. These values 
obtained are in the range that was expected compared to the reported values in the 
literature.  
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 Figure 3.2 Kinetic rates for purified human BHMT, pig and rat liver BHMT 
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Figure 3.3 Kmbetaine Hanes Plot vs Graph Pad Prism 
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Discussion 
It is important when doing enzyme kinetic measurements to do so at initial rate 
conditions. This means, ideally, that the consumption of substrate must be kept to a 
minimum so there is no accumulation of products and the substrate concentrations do 
not significantly change over the assay period. In this assay, the substrate (betaine) 
concentration was as low as 250 µM and at this low substrate concentration about 10% 
of the substrate was converted to product, and much less at the higher substrate 
concentrations tested. As betaine concentrations increased, Met production increased 
until saturation was reached. The data reported here indicate that the variation in the 
Km for betaine toward various BHMT enzymes is not nearly as great as reported in the 
literature. 
The inability of betaine treatment to normalize tHcy in homocystinurics has led to the 
search for alternative methyl donors that might be better substrates for BHMT, as 
determined by high kcat values, and whose demethylated products might be weaker 
inhibitors of the enzyme. A primary objective of this study was to characterize two 
sulfonium analogs of betaine, DMSA and DMSP, to see if they have higher turnover 
rates compared to betaine, but this objective was not met due to technical difficulties 
and time allotted to this project. These studies will be continued by other personnel. 
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Summary 
This work demonstrated that the Km of betaine for the human, rat and pig BHMT 
enzymes are similar and range between 0.5 to 1.8 mM. The differences in Km values 
between these enzymes are relatively small compared to the values previously reported 
in the literature, and support the hypothesis that some experimental values were in error 
most likely due to the overconsumption of betaine at low substrate concentrations. A 
primary objective of this research was to characterize the kinetic properties of DMSA 
and DMSP as a first step to determine if they might be useful alternatives to betaine 
treatment for the treatment of homocystinuria, but due to time limitation and technical 
difficulties, it was only possible to determine the Km for betaine. Future studies will 
complete these unmet objectives. 
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